Stable bortezomib formulations
Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
1. An extended potency, ready to inject pharmaceutical parenteral composition in a vial, the composition comprising:
a single-phase liquid formulation comprising a substantially non-aqueous solvent system suitable for injection, an aqueous buffer, and bortezomib, wherein the bortezomib is present in the formulation at a therapeutically effective concentration;
wherein the single-phase liquid formulation is formulated such that at least 95% of the bortezomib remain as active ingredient after storage at ambient conditions for at least three months;
wherein the substantially non-aqueous solvent system comprises more than 50 vol % propylene glycol; and
wherein the liquid formulation and bortezomib are present in the vial in a quantity suitable for at least two independent and distinct administrations.
2. The composition of claim 1 wherein the substantially non-aqueous solvent system consists essentially of propylene glycol.
3. The composition of claim 1 wherein the formulation comprises at least 75 vol % propylene glycol.
4. The composition of claim 1 wherein the formulation comprises at least 90 vol % propylene glycol.
5. The composition of claim 1 wherein the buffer is an aqueous acetate buffer.
6. The composition of claim 1 wherein the buffer has a pH between 2.0 and 4.0.
7. The composition of claim 1 wherein the buffer has a pH that is equal or less than 4.0, and wherein the single-phase liquid formulation has not undergone lyophilization before storage at ambient conditions for at least three months.
8. The composition of claim 1 wherein the bortezomib is present at a concentration of between 1 mg/ml and 5 mg/ml.
9. A method of stabilizing bortezomib in a liquid pharmaceutical composition that includes bortezomib in a therapeutically effective amount, comprising:
formulating a ready to inject single-phase liquid formulation from a substantially non-aqueous solvent system suitable for injection, an aqueous buffer, and bortezomib;
wherein the solvent system comprises more than 50 vol % propylene glycol and wherein the bortezomib is present in the formulation at a therapeutically effective concentration;
adjusting the pH of the buffer such that the single-phase liquid formulation has a pH that is equal or less than 4.0; and
placing the single-phase liquid formulation in a vial, optionally in a quantity suitable for at least two independent and distinct administrations.
10. The method of claim 9 wherein the single-phase liquid formulation is formulated such that at least 98% of the bortezomib remain as active ingredient after storage at ambient conditions for at least three months.
11. The method of claim 10 wherein the single-phase liquid formulation comprises ethanol and propylene glycol, or exclusively propylene glycol.
12. The method of claim 9 wherein the single-phase liquid formulation includes the aqueous buffer and is formulated such that at least 98% of the bortezomib remain as active ingredient after storage at ambient conditions for at least three months.
13. The method of claim 12 wherein the single-phase liquid formulation comprises at least 75 vol % propylene glycol.
14. The method of claim 13 wherein the aqueous buffer is acetate buffer.
15. The method of claim 12 wherein the pH of the buffer is adjusted such that the single-phase liquid formulation has a pH that is between 2.7. and 3.3.
16. A method of maintaining potency of a liquid pharmaceutical composition that contains bortezomib by reducing degradation of bortezomib in a liquid formulation, the method comprising:
preparing a single-phase ready to inject liquid formulation from a substantially non-aqueous solvent system suitable for injection, and bortezomib;
wherein the substantially non-aqueous solvent system comprises more than 50 vol % propylene glycol;
including an aqueous buffer into the formulation and adjusting the pH of the buffer to a value between 2.0 and 4.0 to thereby reduce formation of at least one degradation product as compared to the formulation without buffer; and
wherein the at least one degradation product is selected form the group consisting of an amide degradation product, a carboxylic acid degradation product, a first carbinolamide degradation product, and a second carbinolamide degradation product; and
placing the single-phase liquid formulation in a multi-use vial, optionally in a quantity suitable for at least two independent and distinct administrations.
17. The method of claim 16 wherein the aqueous buffer is selected from the group consisting of an acetate buffer, a citrate buffer, and a potassium hydrogen phthalate/HCl buffer.
18. The method of claim 16 wherein the pH of the buffer is adjusted to a value between 2.7 and 3.3 to thereby reduce formation of the amide degradation product, the carboxylic acid degradation product, the first carbinolamide degradation product, and the second carbinolamide degradation product.
19. The method of claim 18 wherein the buffer is an acetate buffer.
20. The method of claim 16 wherein the bortezomib is present in the liquid pharmaceutical composition at a concentration of 1 mg/ml and 5 mg/ml.